Mark Versavel

2.1k total citations
21 papers, 1.2k citations indexed

About

Mark Versavel is a scholar working on Psychiatry and Mental health, Neurology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Mark Versavel has authored 21 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Psychiatry and Mental health, 7 papers in Neurology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Mark Versavel's work include Epilepsy research and treatment (5 papers), Pharmacological Effects and Toxicity Studies (5 papers) and Bipolar Disorder and Treatment (4 papers). Mark Versavel is often cited by papers focused on Epilepsy research and treatment (5 papers), Pharmacological Effects and Toxicity Studies (5 papers) and Bipolar Disorder and Treatment (4 papers). Mark Versavel collaborates with scholars based in United States, United Kingdom and France. Mark Versavel's co-authors include James P. Young, Emmanuelle Vincent, Rafael Gálvez, Pascal Maisonobe, David A. Cherry, R. Sabatowski, Hilary A. Feister, Robert van Seventer, Rainer Freynhagen and Thomas R. Tölle and has published in prestigious journals such as Stroke, Pain and Neurosurgery.

In The Last Decade

Mark Versavel

20 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Versavel United States	13	691	422	301	289	177	21	1.2k
U. Sharma United States	6	754 1.1×	427 1.0×	189 0.6×	284 1.0×	243 1.4×	13	1.1k
T. Griesing United States	9	752 1.1×	370 0.9×	274 0.9×	363 1.3×	208 1.2×	19	1.2k
Keith M. Gregg United States	13	860 1.2×	186 0.4×	426 1.4×	279 1.0×	496 2.8×	21	1.8k
Kristina B. Svendsen Denmark	14	286 0.4×	405 1.0×	56 0.2×	307 1.1×	141 0.8×	24	1.1k
Philip T. Malan United States	11	1.1k 1.5×	228 0.5×	73 0.2×	594 2.1×	394 2.2×	14	1.9k
Wolfgang Meder Germany	9	308 0.4×	120 0.3×	225 0.7×	133 0.5×	81 0.5×	9	828
Naohito Shimoyama Japan	24	956 1.4×	133 0.3×	116 0.4×	217 0.8×	292 1.6×	48	1.6k
Robert A. Swarm United States	11	498 0.7×	53 0.1×	203 0.7×	245 0.8×	186 1.1×	26	1.0k
Steve Quessy United States	12	393 0.6×	205 0.5×	68 0.2×	192 0.7×	280 1.6×	19	755
Thomas P. Enggaard Denmark	14	405 0.6×	112 0.3×	70 0.2×	295 1.0×	528 3.0×	24	999

Countries citing papers authored by Mark Versavel

Since Specialization

Citations

This map shows the geographic impact of Mark Versavel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Versavel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Versavel more than expected).

Fields of papers citing papers by Mark Versavel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Versavel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Versavel. The network helps show where Mark Versavel may publish in the future.

Co-authorship network of co-authors of Mark Versavel

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Versavel. A scholar is included among the top collaborators of Mark Versavel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Versavel. Mark Versavel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Papapetropoulos, Spyros, Margaret Lee, Hyder A. Jinnah, et al.. (2021). A Phase 2 Proof‐of‐Concept, Randomized, Placebo‐Controlled Trial of CX‐8998 in Essential Tremor. Movement Disorders. 36(8). 1944–1949. 21 indexed citations

Naik, Himanshu, et al.. (2020). Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers. Clinical and Translational Science. 14(4). 1272–1279. 6 indexed citations

Dunbar, Joi, Mark Versavel, Yuan Zhao, et al.. (2019). Evaluation of the Pharmacokinetic Interaction Between the Voltage‐ and Use‐Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy Volunteers. Clinical Pharmacology in Drug Development. 9(1). 62–73. 10 indexed citations

Hey, John A., Yongxin Yu, Mark Versavel, et al.. (2017). Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease. Clinical Pharmacokinetics. 57(3). 315–333. 93 indexed citations

Sramek, John J., Larry W. Hardy, P. R. Bieck, et al.. (2016). Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP‐432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects. CNS Neuroscience & Therapeutics. 22(5). 404–412. 3 indexed citations

Hey, John A., Susan Abushakra, Aidan Power, et al.. (2016). P2‐012: Phase 1 Development of ALZ‐801, a Novel Beta Amyloid Anti‐Aggregation Prodrug of Tramiprosate with Improved Drug Properties, Supporting Bridging to The Phase 3 Program. Alzheimer s & Dementia. 12(7S_Part_12). 3 indexed citations

Versavel, Mark. (2015). Efficacy and safety of the novel sodium channel Blocker CNV1014802 in Trigeminal Neuralgia and Lumbosacral Radiculopathy. Journal of Pain & Relief. 2 indexed citations

Fertig, Evan, Brandy Fureman, Gregory K. Bergey, et al.. (2014). Inclusion and exclusion criteria for epilepsy clinical trials–Recommendations from the April 30, 2011 NINDS workshop. Epilepsy Research. 108(5). 825–832. 13 indexed citations

Versavel, Mark, M. Zühlsdorf, Sigrun Unger, Georg Wensing, & J. Kuhlmann. (2011). Concentration-Effect Relationships of Alcohol in a Computerised Psychometric Test System. Arzneimittelforschung. 55(5). 289–295.

10.

Bowden, Charles L., Eduard Vieta, Kathleen Ice, et al.. (2010). Ziprasidone Plus a Mood Stabilizer in Subjects With Bipolar I Disorder. The Journal of Clinical Psychiatry. 71(2). 130–137. 93 indexed citations

11.

Stewart, Michelle, Melissa P. DelBello, Mark Versavel, & David Keller. (2009). Psychosocial Functioning and Health-Related Quality of Life in Children and Adolescents Treated with Open-Label Ziprasidone for Bipolar Mania, Schizophrenia, or Schizoaffective Disorder. Journal of Child and Adolescent Psychopharmacology. 19(6). 635–640. 11 indexed citations

12.

DelBello, Melissa P., Mark Versavel, Kathleen Ice, David Keller, & Jeffrey Miceli. (2008). Tolerability of Oral Ziprasidone in Children and Adolescents with Bipolar Mania, Schizophrenia, or Schizoaffective Disorder. Journal of Child and Adolescent Psychopharmacology. 18(5). 491–499. 42 indexed citations

13.

Gandelman, Kuan, Jeffrey Alderman, Paul Glue, et al.. (2008). The Impact of Calories and Fat Content of Meals on Oral Ziprasidone Absorption. The Journal of Clinical Psychiatry. 70(1). 58–62. 38 indexed citations

14.

Tölle, Thomas R., et al.. (2007). Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: A randomized, double‐blind study. European Journal of Pain. 12(2). 203–213. 171 indexed citations

15.

García‐Borreguero, Diego, et al.. (2007). Efficacy and tolerability of sumanirole in restless legs syndrome: A phase II, randomized, double-blind, placebo-controlled, dose–response study. Sleep Medicine. 8(2). 119–127. 17 indexed citations

16.

Seventer, Robert van, et al.. (2006). Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13‐week, randomized trial. Current Medical Research and Opinion. 22(2). 375–384. 202 indexed citations

17.

Walters, Matthew R., Markku Kaste, Kennedy R. Lees, et al.. (2005). The AMPA Antagonist ZK 200775 in Patients with Acute Ischaemic Stroke: A Double-Blind, Multicentre, Placebo-Controlled Safety and Tolerability Study. Cerebrovascular Diseases. 20(5). 304–309. 39 indexed citations

18.

Sabatowski, R., Rafael Gálvez, David A. Cherry, et al.. (2004). Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 109(1). 26–35. 397 indexed citations

19.

Sulter, Geert, Markku Kaste, Kennedy R. Lees, et al.. (2002). AMPA Antagonist ZK200775 in Patients With Acute Ischemic Stroke. Stroke. 33(12). 2813–2818. 51 indexed citations

20.

Versavel, Mark, et al.. (1988). Giant Aneurysm Arising from the Anterior Cerebral Artery and Causing an Isolated Homonymous Hemianopsia. Neurosurgery. 22(3). 560–563. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact